BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38630995)

  • 1. Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.
    Yang Q; Zhang F; Hao Z; Zhuang J; Huo L
    Clin Nucl Med; 2024 Jun; 49(6):592-593. PubMed ID: 38630995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokine receptor-4 targeted PET/CT with
    Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging CXCR4 receptors expression for staging multiple myeloma by using
    Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
    Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
    Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced splenic uptake on
    Kraus S; Klassen P; Kircher M; Dierks A; Habringer S; Gäble A; Kortüm KM; Weinhold N; Ademaj-Kospiri V; Werner RA; Schirbel A; Buck AK; Herhaus P; Wester HJ; Rosenwald A; Weber WA; Einsele H; Keller U; Rasche L; Lapa C
    Theranostics; 2022; 12(13):5986-5994. PubMed ID: 35966583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma.
    Pan Q; Luo Y; Cao X; Li J
    Clin Nucl Med; 2021 Jan; 46(1):90-92. PubMed ID: 33181744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4-Directed PET/CT with [
    Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
    Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [
    Kosmala A; Duell J; Schneid S; Serfling SE; Higuchi T; Weich A; Lapa C; Hartrampf PE; Raderer M; Einsele H; Buck AK; Topp MS; Schlötelburg W; Werner RA
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):749-755. PubMed ID: 37943339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
    Luo Y; Pan Q; Feng J; Cao X; Li F
    Clin Nucl Med; 2018 Jul; 43(7):548-550. PubMed ID: 29742593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
    Chen Z; Xue Q; Yao S
    Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [
    Serfling SE; Lapa C; Dreher N; Hartrampf PE; Rowe SP; Higuchi T; Schirbel A; Weich A; Hahner S; Fassnacht M; Buck AK; Werner RA
    Mol Imaging Biol; 2022 Aug; 24(4):659-665. PubMed ID: 35312939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
    Jacobs SM; Wesseling P; de Keizer B; Tolboom N; Ververs FFT; Krijger GC; Westerman BA; Snijders TJ; Robe PA; van der Kolk AG
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):481-491. PubMed ID: 33550492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary Cryptococcosis Accidentally Detected by 68Ga-Pentixafor PET/CT in a Patient With Multiple Myeloma.
    Pan Q; Luo Y; Cao X; Li J; Li F
    Clin Nucl Med; 2020 May; 45(5):423-425. PubMed ID: 32209881
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
    J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
    [No Abstract]   [Full Text] [Related]  

  • 16. Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on
    Xu L; Tetteh G; Lipkova J; Zhao Y; Li H; Christ P; Piraud M; Buck A; Shi K; Menze BH
    Contrast Media Mol Imaging; 2018; 2018():2391925. PubMed ID: 29531504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT.
    Pan Q; Luo Y; Cao X; Ma Y; Li F
    Clin Nucl Med; 2018 Jun; 43(6):462-463. PubMed ID: 29538035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of [ 68 Ga]Ga-Pentixafor PET/CT in malignant melanoma: a pilot study.
    Manafi-Farid R; Mahini M; Mirshahvalad SA; Fallahi B; Fard-Esfahani A; Emami-Ardekani A; Eftekhari M; Mousavi SA; Beiki D
    Nucl Med Commun; 2024 Mar; 45(3):221-228. PubMed ID: 38214076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
    Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
    Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4-directed [
    Chaman Baz AH; van de Wiel E; Groenewoud H; Arntz M; Gotthardt M; Deinum J; Langenhuijsen J
    BMJ Open; 2022 Aug; 12(8):e060779. PubMed ID: 35998969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.